top of page
iPharmaCenter
News | Blogs | Healthcare | Consulting
Contact:
info@ipharmacenter.com
Home
Pharma
North America
US FDA Approvals
Canada Drug Healthcare News
APAC
China Drug Approvals
India Drug Approvals
APAC - Drug Approvals
Japan Drug Approvals | Healthcare
Europe
EMA News
LACAM
Brazil - Drug approvals
Healthcare News
US Healthcare News
US Payer News
APAC - Healthcare News
Europe Healthcare News
Lacam Healthcare News
Healthcare Policies
Disease News
Immunology
Oncology
Infections_Vaccines
Cardiovascular
Kidney Diseases
Metabolic Diseases
Women Health
Neurology
Conferences
Others
COVID-19
Contact
All Posts
Healthcare Systems
News
Conferences
Know your disease
COVID
Japan drug approvals
USA Pharma News | Healthcare News
Europe Pharma News
Japan drug approvals
Australia Pharma & Healthcare News
Canada Pharma and Healthcare News
Asia | Pharma | Healthcare News
Indication News
Latam
US FDA News
CMS News
India Drug Healthcare
China Drug Approvals
Europe Healthcare News
APAC Drug approvals
US_PayerNews
Australia TGA Approvals
Biosimilars
Radioligand therapy
Chikungunya News
NICE recommendations
G-BA Assessment Outcomes
HAS Assessment Outcomes
Neurology
Immunology
Search
Log in / Sign up
Keytruda failed to meet the primary endpoints in mCRPC and 1L uHCC | iParmaCenter
ipharmaservices
Aug 4, 2022
Breast Cancer News | Blogs | Keytruda, Trodelvy was approved for TNBC | iPhamaCenter
ipharmaservices
Jan 17, 2022
ESMO 2020
ipharmaservices
Sep 19, 2020
To strengthen the oncology portfolio, Merck collaborated with Seattle Genetics, and Gilead acquired
ipharmaservices
Sep 18, 2020
Bayer submitted vericiguat for market authorization in China
ipharmaservices
Aug 28, 2020
bottom of page